Embryo development

17
Embryo development Day 0 Day 1 Day 2 Day 3 Day 5 Day 6 Day 4

description

Embryo development. Day 0. Day 1. Day 2. Day 3. Day 4. Day 5. Day 6. Embryo transfer. Replacing 1-2 embryos to reduce the risk of multiple pregnancies. IVF. An effective treatment for different causes of infertility Live birth rate 30-50% ~25-30% of embryos will implant. - PowerPoint PPT Presentation

Transcript of Embryo development

Page 1: Embryo development

Embryo developmentEmbryo development

Day 0 Day 1 Day 2 Day 3 Day 5 Day 6Day 4

Page 2: Embryo development

Embryo transfer

Replacing 1-2 embryosto reduce the risk of

multiple pregnancies

Page 3: Embryo development

IVFIVF

An effective treatment for different causes of infertility

Live birth rate 30-50% ~25-30% of embryos will implant

Page 4: Embryo development

Factors affecting IVF success Factors affecting IVF success

1. Age of women

2. Number of treatment cycles

3. Ovarian response

4. Others: smoking, obesity, hydrosalpinges,

uterine fibroids etc.

5. Endometrial receptivity

Page 5: Embryo development

Complications Complications

1. Ovarian stimulation Ovarian hyperstimulation syndrome (OHSS) Ovarian carcinoma

2. Egg collection Bleeding Pelvic infection

3. Embryo transfer Multiple pregnancy Ectopic pregnancy

4. Psychological

Page 6: Embryo development

Reduction of multiple pregnancy Reduction of multiple pregnancy

1. Reducing the number of embryos

replaced i.e. replace SINGLE embryo

or blastocyst

2. Fetal reduction

Page 7: Embryo development

1+1 Vs 2 embryos1+1 Vs 2 embryos

1+1 (n=330)

2(n=331)

P value

Live births

Fresh cycle 91 (27.6%) 142 (42.9%) <0.001

Frozen cycle 29 (16.4%) ----

Cumulative cycles 128 (38.8%) 142 (42.9%) NS

Multiple births 1 (0.8%) 47 (33.1%) <0.001

(Thurin et al., NEJM, 2004)

Page 8: Embryo development

OHSSOHSS

5 % moderate (Delvigne 2002)

2% required hospitalization (Papanikolauo 2005)

Life-threatening condition Estimated mortality 3/100,000 cycles

Page 9: Embryo development

OHSSOHSS

Ovarian enlargement and abdominal distension

Nausea, vomiting & abdominal pain Decrease in urine output Ascites, hydrothorax & generalized oedema Haemoconcentration & thromboembolism Liver failure and renal failure

Page 10: Embryo development

OHSS managementOHSS management

Reduced by identifying high risk patients and choosing appropriate stimulation protocols (GnRH antagonist protocol, mild stimulation, progesterone for luteal phase support)

In cases of excessive response – agonist to induce LH surge in antagonist cycles, freeze all embryos, hydroxyethyl starch and cabergoline

Page 11: Embryo development

OHSS-Principles of managementOHSS-Principles of management

Careful monitor of vital signs, BW, abdominal girth, CBP, Hct, RFT, LFT, clotting studies

Pelvic U/S to assess ascites & ovaries CXR if respiratory symptoms or signs Mild/moderate can be managed as outpatient Paracetamol/codeine for pain; avoid NSAID Admit for inpatient management in severe

cases

Page 12: Embryo development

OHSS-Principles of managementOHSS-Principles of management

Adequate fluid intake – IV fluid (N/S and colloids) if the patient cannot tolerate oral fluid

Diuretics should be avoided unless oliguria persists despite adequate intravascular expansion and under careful haemodynamic monitoring

U/S guided paracentesis in case of tense ascites

Anticoagulation should be considered in patients admitted for severe or critical OHSS

Page 13: Embryo development

Congenital abnormalitiesCongenital abnormalities

~30% increase in the risk of birth defects following IVF (Hansen et al., HRU, 2013)

Higher rate of de-novo chromosomal anomalies in ICSI offsprings (1.6% Vs 0.5%)mainly higher no. of sex chromosomal anomalies

and partly a higher no. autosomal structural anomalies (Bonduelle et al., 2002)

Page 14: Embryo development

1.32 (1.24, 1.42)

Page 15: Embryo development

Neonatal outcomes of singletons following ART Vs spontaneous conceptions

Neonatal outcomes of singletons following ART Vs spontaneous conceptions

Relative risk (95% CI)

Very preterm (< 32 weeks) 3.27 (2.03 to 5.28) Preterm (< 37 weeks) 2.04 (1.80 to 2.32) Very low birth weight (< 1500 g) 3.00 (2.07 to 4.36)Low birth weight (< 2500 g) 1.70 (1.50 to 1.92)Small for gestational age 1.40 (1.15 to 1.71) Caesarean section 1.54 (1.44 to 1.66)NICU admission 1.27 (1.16 to 1.40) Perinatal mortality 1.68 (1.11 to 2.55)

(Helmerhorst et al., BMJ, 2004)

Page 16: Embryo development

Longterm health outcomesLongterm health outcomes

May increase the incidence of high blood pressure, elevated fasting glucose, total body fat composition, advancement of bone age and potentially subclinical thyroid disorder

Increase the incidence of cerebral palsy and neurodevelopmental delay related to prematurity and low birthweight

Potential increase in the prevalence of early adulthood clinical depression and binge drinking

(Hart and Norman, HRU, 2013)

Page 17: Embryo development

Thank you for attention